These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19093965)

  • 1. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.
    Masopust D
    J Intern Med; 2009 Jan; 265(1):125-37. PubMed ID: 19093965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ; Schwartz EJ
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress towards an AIDS mucosal vaccine: an overview.
    Yuki Y; Nochi T; Kiyono H
    Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S35-44. PubMed ID: 17652028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
    McMichael A; Hanke T
    Nat Rev Immunol; 2002 Apr; 2(4):283-91. PubMed ID: 12001999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.
    Newman MJ
    Curr Opin Investig Drugs; 2002 Mar; 3(3):374-8. PubMed ID: 12054082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
    Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
    Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.
    Ahlers JD; Belyakov IM
    Trends Immunol; 2010 Mar; 31(3):120-30. PubMed ID: 20089450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hitting HIV where it hurts: an alternative approach to HIV vaccine design.
    Altfeld M; Allen TM
    Trends Immunol; 2006 Nov; 27(11):504-10. PubMed ID: 16997629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells.
    Lu L; Zhu Y; Diao J; Wang Z; Chen YH
    Vaccine; 2008 Feb; 26(6):845-52. PubMed ID: 18191003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection from secondary human immunodeficiency virus type 1 infection in chimpanzees suggests the importance of antigenic boosting and a possible role for cytotoxic T cells.
    Balla-Jhagjhoorsingh SS; Mooij P; ten Haaft PJ; Bogers WM; Teeuwsen VJ; Koopman G; Heeney JL
    J Infect Dis; 2001 Jul; 184(2):136-43. PubMed ID: 11424009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
    Belyakov IM; Ahlers JD
    Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of an AIDS vaccine: status report].
    Girard MP
    Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
    Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
    Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the mechanisms and limitations of immune control of HIV.
    Davenport MP; Ribeiro RM; Zhang L; Wilson DP; Perelson AS
    Immunol Rev; 2007 Apr; 216():164-75. PubMed ID: 17367342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
    Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.